A very early stage biotech opportunity with links to big pharma. We are seeing small scattered call buying today.
Back in September, we mentioned this stock on news about its partnership with Microsoft. Since then it has pulled back mainly due to rotation from Growth to Value. We believe it has now bottomed and presenting a buying opportunity.
We are following up on a recent IPO idea published on our telegram channel. This Medtech company looks towards a post COVID expansion in Europe and Asia.
This early stage media company sells at 20% percent discounted valuation to Netflix. It has double the revenue growth, higher margins and its service is only priced at $15/year!
The move from Growth stocks to Value names has been quick and decisive. We look at a big name tech stock to take advantage of a rotation back into growth.
JP Morgan says COVID distribution is likely to positive affect a value stock in the healthcare sector. We outline how to take advantage of this.
A leader in streaming media recently increased monthly subscription pricing. Will there be a spike in the churn rate in Q4? We present a bullish case for the stock with a clear price target.
If COVID cases continue to rise this winter, this stock stands to gain. Currently, revenue growth rates exceed 100% year over year.
Reliance on coal for energy in the US continues to fall, even under the Trump administration. Solar power is on the rise. As the US market pulls back, US tech stocks underwhelming guidance is likely misleading.
A leading sports betting stock has come on hard times, as NFL teams are contracting COVID. But earnings are coming soon. Its to early to count this one stock out.